Therefore, CA9 has gained interest as a biomarker in malignancies.[10] Increased CA9 serum levels have been associated with outcome and prognosis in prostate cancer[11], renal cell cancer[12–14], gastric cancer[15], breast cancer[16], vulvar cancer[17] and cervical cancer[18]. This evidence concerns the gene CA9 and breast carcinoma.